dalteparin has been researched along with Obesity in 65 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 9.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients." | 7.73 | Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. ( Cohen, AT; Goldhaber, SZ; Kucher, N; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2005) |
| "These results suggest that doses of dalteparin in obese patients should be based on total body weight or an adjusted body weight, but not lean body weight." | 7.70 | The effect of body weight on dalteparin pharmacokinetics. A preliminary study. ( Duffull, SB; Yee, JY, 2000) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 5.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 5.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| " Lean body weight was proposed as a suitable weight scalar for induction of anaesthesia with propofol whereas total body weight for maintenance of anaesthesia with propofol and depolarizing muscle relaxants." | 4.98 | Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies. ( Curtain, C; Hussain, Z; Mirkazemi, C; Zaidi, STR, 2018) |
| "We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients." | 3.73 | Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. ( Cohen, AT; Goldhaber, SZ; Kucher, N; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2005) |
| "These results suggest that doses of dalteparin in obese patients should be based on total body weight or an adjusted body weight, but not lean body weight." | 3.70 | The effect of body weight on dalteparin pharmacokinetics. A preliminary study. ( Duffull, SB; Yee, JY, 2000) |
| "To review the evidence cited in recent consensus documents providing recommendations for drug dosing for venous thromboembolism (VTE) prophylaxis in obese trauma patients." | 3.01 | Pharmacologic venous thromboembolism prophylaxis in obese trauma patients. ( Barletta, JF; Erstad, BL, 2023) |
| "Compared with fixed dosing daily, weight-based dosing twice daily more effectively achieved prophylactic anti-Xa levels without reaching the therapeutic range." | 2.82 | A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. ( Caballero, DC; McNulty, J; Neeper, JM; Serra, AE; Stephenson, ML, 2016) |
| "1 IU/mL was considered subtherapeutic and the final dosage requirement was recorded." | 2.80 | Standard Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis Is Not Sufficient for Most Patients Within a Trauma Intensive Care Unit. ( Ahmed, N; Allen, J; Brevard, SB; Frotan, AM; Gonzalez, RP; Replogle, WH; Rostas, JW; Simmons, JD; Thacker, D, 2015) |
| " It is a hydrophilic molecule that is, predominantly, eliminated renally with few data to support dosing for subjects with renal impairment and/or obesity." | 2.75 | Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2010) |
| "Data were obtained from a randomized controlled trial (n = 118) that compared conventional dosing of enoxaparin (product label) with an individualized dosing regimen." | 2.74 | Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2009) |
| "Based on Anti-Xa, no dosage adjustments are required in obese patients." | 2.71 | Dosage of enoxaparin among obese and renal impairment patients. ( Almanric, K; Bazinet, A; Blais, N; Brunet, C; Caron, S; Lalonde, L; Martineau, J; Turcotte, I, 2005) |
| "This pharmacodynamic study examined weight-based dosing of the low molecular weight heparin (LMWH), tinzaparin, in heavyweight/obese subjects." | 2.70 | Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Leathers, T; Leese, PT, 2002) |
| " Pharmacodynamic analysis of activated partial thromboplastin time showed similar results in obese and nonobese volunteers after both intravenous and subcutaneous administration." | 2.70 | The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. ( Boutouyrie, B; Harding, N; Jariwala, N; Le Liboux, A; Miro, A; Montay, G; Ozoux, ML; Sanderink, GJ; Shukla, U, 2002) |
| "The current debate over the optimal Enoxaparin prophylactic dosing strategies in obese patients centre around whether it should be based on the actual weight of the patient (i." | 2.55 | Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed. ( Ball, P; He, Z; Morrissey, H, 2017) |
| "To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population." | 2.55 | Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients. ( Gales, MA; Horyna, TJ; Sandmann, EA; Walker, CK, 2017) |
| " Despite the potential for increased pharmacotherapy among obese patients, there is a paucity of dosing guidelines for this special population." | 2.52 | Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents. ( van den Anker, JN; Vaughns, JD; Ziesenitz, VC, 2015) |
| " Recently, the use of safe-dose recombinant tissue-type plasminogen activator (rTPA) has been proposed for the treatment of moderate PE demonstrating to be safe and more effective than standard anticoagulation." | 2.50 | [Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature]. ( Cannone, M; La Torre, PP; Mele, A; Mele, M, 2014) |
| "To evaluate the appropriate dosing of enoxaparin as a venous thromboembolism (VTE) prophylaxis in hospitalized obese patients." | 2.49 | Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients. ( Alsharhan, M; Cooper, MR; Durand, C; Willett, KC, 2013) |
| "Despite the growing epidemic of obesity in the United States, dosing medications in such patients remains poorly studied and understood." | 2.46 | Pharmacotherapy in the critically ill obese patient. ( Medico, CJ; Walsh, P, 2010) |
| "Enoxaparin is a low-molecular-weight heparin (LMWH) that differs substantially from unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic properties." | 2.42 | Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. ( Fareed, J; Hoppensteadt, D; Iqbal, O; Jeske, W; Ma, Q; Sheikh, T; Walenga, J, 2003) |
| " Weight-based dosing is suitable for obese patients." | 1.91 | The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients. ( Hackeng, CM; Knibbe, CAJ; Mast, L; Peeters, MYM; Söhne, M; van den Broek, MPH, 2023) |
| "Obesity is a well-recognised risk factor for venous thromboembolism, and increased dosing of pharmacological prophylaxis is recommended in obese inpatients." | 1.72 | Improving compliance with venous thromboembolism prophylaxis guidelines in obese inpatients. ( Bortz, H; Chee, A; McFadyen, JD; Yip, J, 2022) |
| " To further mechanistically explore obesity-associated differences in anti-Xa concentration, a pediatric physiologically-based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity." | 1.72 | Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity. ( Carreño, FO; Edginton, AN; Gerhart, JG; Gonzalez, D; Hornik, CP; Kirkpatrick, CM; Kumar, KR; Lee, CR; Loop, MS; Sinha, J, 2022) |
| " We investigated whether our dosage regimen of enoxaparin resulted in similar serum aFXa levels in female and male patients undergoing bariatric surgery." | 1.72 | Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis. ( Duprée, A; Izbicki, J; Lautenbach, A; Mann, O; von Kroge, P; Wagner, J; Wolter, S; Wruck, H, 2022) |
| " Our objective was to evaluate the efficacy of enoxaparin dosed 40 mg twice daily in achieving prophylactic plasma anti-Xa levels in obese burn patients." | 1.62 | Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients. ( Jones, S; King, B; McKinzie, BP; Nizamani, R; Williams, FN, 2021) |
| "Standard fixed-dose enoxaparin dosing regimens may not provide adequate prophylaxis against venous thromboembolism among obese hospitalized patients." | 1.62 | Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. ( Davis, S; Gibson, CM; Hall, C; Schillig, JM, 2021) |
| "Current treatment dose of enoxaparin is based on total body weight (TBW), however dosage in obesity remains unclear." | 1.51 | Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. ( Barras, M; van Oosterom, N; Winckel, K, 2019) |
| "Body weight has a significant impact on blood volume and drug clearance." | 1.42 | Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. ( Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015) |
| "The mean initial anti-Xa level was higher in obese pediatric patients compared with non-obese pediatric patients, but a dosage adjustment was not required." | 1.39 | Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin. ( Bomgaars, L; Kim, S; Mahoney, D; Moffett, BS; Richard, AA; Yee, DL, 2013) |
| "Limited data exist regarding the efficacy of weight-based dosing of low-molecular weight heparin for venous thromboembolism (VTE) prophylaxis in obese trauma patients." | 1.39 | Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. ( Bickford, A; Bledsoe, J; Dickerson, J; Johnston, R; Majercik, S; Smith, K; White, T, 2013) |
| "Weight-based dosing for enoxaparin is recommended in the 2008 American College of Chest Physicians (ACCP) guidelines for venous thromboembolism (VTE) prophylaxis." | 1.37 | Increased enoxaparin dosing is required for obese children. ( Dunlap, M; Johnson, PN; Lewis, TV; Nebbia, AM, 2011) |
| " Enoxaparin was dosed as 1 mg/kg regardless of body weight without maximum." | 1.36 | Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. ( Antman, EM; Aylward, PE; Becker, RC; Califf, RM; Col, JJ; Ducas, J; Ferguson, JJ; Gallo, R; Goodman, SG; Langer, A; Levine, GN; Mahaffey, KW; Spinler, SA; Tonev, ST; White, HD, 2010) |
| "Body weight is an important risk factor for thromboses and is used in algorithms to determine dosages in prophylaxis." | 1.35 | A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. ( Grohs, JG; Lunzer, A; Vavken, P, 2009) |
| "To evaluate how enoxaparin is dosed in contemporary clinical practice as a function of patients' total body weight (TBW) and body mass index (BMI), and to determine any association between dose and major bleeding." | 1.35 | Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. ( Alexander, KP; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT; Spinler, SA, 2009) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 1.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| "Enoxaparin dosing is currently based on total body weight." | 1.32 | Development of a dosing strategy for enoxaparin in obese patients. ( Duffull, SB; Green, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.54) | 18.2507 |
| 2000's | 26 (40.00) | 29.6817 |
| 2010's | 25 (38.46) | 24.3611 |
| 2020's | 13 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mast, L | 1 |
| Peeters, MYM | 1 |
| Söhne, M | 1 |
| Hackeng, CM | 1 |
| Knibbe, CAJ | 1 |
| van den Broek, MPH | 1 |
| Galimov, OV | 1 |
| Galeev, FS | 1 |
| Khanov, VO | 1 |
| Mukhametov, AR | 1 |
| Andreev, PP | 1 |
| Muslimova, LR | 1 |
| Aminova, LN | 1 |
| Heizmann, M | 1 |
| Baerlocher, GM | 1 |
| Steinmann, F | 1 |
| Horber, FF | 1 |
| Wuillemin, W | 1 |
| Vavken, P | 1 |
| Lunzer, A | 1 |
| Grohs, JG | 1 |
| Wagner, J | 1 |
| Wruck, H | 1 |
| Lautenbach, A | 1 |
| von Kroge, P | 1 |
| Wolter, S | 1 |
| Mann, O | 1 |
| Izbicki, J | 1 |
| Duprée, A | 1 |
| Gerhart, JG | 1 |
| Carreño, FO | 1 |
| Loop, MS | 1 |
| Lee, CR | 1 |
| Edginton, AN | 1 |
| Sinha, J | 1 |
| Kumar, KR | 1 |
| Kirkpatrick, CM | 1 |
| Hornik, CP | 1 |
| Gonzalez, D | 1 |
| Chee, A | 1 |
| Bortz, H | 1 |
| Yip, J | 1 |
| McFadyen, JD | 1 |
| Saadoun, R | 1 |
| Bengur, FB | 1 |
| Moroni, EA | 1 |
| Surucu, Y | 1 |
| Veit, JA | 1 |
| Khan, NI | 1 |
| Daniels, K | 1 |
| Rothenberger, SD | 1 |
| Kubik, M | 1 |
| Solari, MG | 1 |
| Sridharan, S | 1 |
| Erstad, BL | 3 |
| Barletta, JF | 3 |
| Carbajal-Mamani, SL | 1 |
| Dideban, B | 1 |
| Schweer, D | 1 |
| Balavage, KT | 1 |
| Chuang, L | 1 |
| Wang, Y | 1 |
| Wang, S | 1 |
| Lee, JH | 1 |
| Amaro, B | 1 |
| Cardenas-Goicoechea, J | 1 |
| Nachega, JB | 1 |
| Ishoso, DK | 1 |
| Otokoye, JO | 1 |
| Hermans, MP | 1 |
| Machekano, RN | 1 |
| Sam-Agudu, NA | 1 |
| Bongo-Pasi Nswe, C | 1 |
| Mbala-Kingebeni, P | 1 |
| Madinga, JN | 1 |
| Mukendi, S | 1 |
| Kolié, MC | 1 |
| Nkwembe, EN | 1 |
| Mbuyi, GM | 1 |
| Nsio, JM | 1 |
| Mukeba Tshialala, D | 1 |
| Tshiasuma Pipo, M | 1 |
| Ahuka-Mundeke, S | 1 |
| Muyembe-Tamfum, JJ | 1 |
| Mofenson, L | 1 |
| Smith, G | 1 |
| Mills, EJ | 1 |
| Mellors, JW | 1 |
| Zumla, A | 1 |
| Mavungu Landu, DJ | 1 |
| Kayembe, JM | 1 |
| Yamashita, S | 1 |
| Nishi, M | 1 |
| Ikemoto, T | 1 |
| Yoshikawa, K | 1 |
| Higashijima, J | 1 |
| Tokunaga, T | 1 |
| Takasu, C | 1 |
| Kashihara, H | 1 |
| Eto, S | 1 |
| Yoshimoto, T | 1 |
| Shimada, M | 1 |
| Gibson, CM | 1 |
| Hall, C | 1 |
| Davis, S | 1 |
| Schillig, JM | 1 |
| McKinzie, BP | 1 |
| Nizamani, R | 1 |
| Jones, S | 1 |
| King, B | 1 |
| Williams, FN | 1 |
| Briggler, R | 1 |
| Matherne, E | 1 |
| Johnson, C | 1 |
| Boehmer, K | 1 |
| He, Z | 1 |
| Morrissey, H | 1 |
| Ball, P | 1 |
| Burns, W | 1 |
| Koelper, N | 1 |
| Barberio, A | 1 |
| Deagostino-Kelly, M | 1 |
| Mennuti, M | 1 |
| Sammel, MD | 1 |
| Dugoff, L | 1 |
| Hussain, Z | 1 |
| Curtain, C | 1 |
| Mirkazemi, C | 1 |
| Zaidi, STR | 1 |
| Ng, QX | 1 |
| Seng, C | 1 |
| Ho, CYX | 1 |
| Yeo, WS | 1 |
| van Oosterom, N | 1 |
| Winckel, K | 1 |
| Barras, M | 1 |
| Bickford, A | 1 |
| Majercik, S | 1 |
| Bledsoe, J | 1 |
| Smith, K | 1 |
| Johnston, R | 1 |
| Dickerson, J | 1 |
| White, T | 1 |
| Willett, KC | 1 |
| Alsharhan, M | 1 |
| Durand, C | 1 |
| Cooper, MR | 1 |
| Mele, M | 1 |
| Mele, A | 1 |
| La Torre, PP | 1 |
| Cannone, M | 1 |
| Sebastian, R | 1 |
| Ghanem, O | 1 |
| DiRoma, F | 1 |
| Milner, SM | 1 |
| Price, LA | 1 |
| Listernick, R | 1 |
| Benya, E | 1 |
| Trainor, J | 1 |
| Kabre, R | 1 |
| Lautz, T | 1 |
| Sharathkumar, A | 2 |
| Liem, R | 1 |
| Bhat, R | 1 |
| Rozenfeld, R | 1 |
| Thompson, A | 1 |
| Vaughns, JD | 1 |
| Ziesenitz, VC | 1 |
| van den Anker, JN | 1 |
| Rostas, JW | 1 |
| Brevard, SB | 1 |
| Ahmed, N | 1 |
| Allen, J | 1 |
| Thacker, D | 1 |
| Replogle, WH | 1 |
| Gonzalez, RP | 1 |
| Frotan, AM | 1 |
| Simmons, JD | 1 |
| Streiff, MB | 1 |
| Holmstrom, B | 1 |
| Ashrani, A | 1 |
| Bockenstedt, PL | 1 |
| Chesney, C | 1 |
| Eby, C | 1 |
| Fanikos, J | 1 |
| Fenninger, RB | 1 |
| Fogerty, AE | 1 |
| Gao, S | 1 |
| Goldhaber, SZ | 2 |
| Hendrie, P | 1 |
| Kuderer, N | 1 |
| Lee, A | 1 |
| Lee, JT | 1 |
| Lovrincevic, M | 1 |
| Millenson, MM | 1 |
| Neff, AT | 1 |
| Ortel, TL | 1 |
| Paschal, R | 1 |
| Shattil, S | 1 |
| Siddiqi, T | 1 |
| Smock, KJ | 1 |
| Soff, G | 1 |
| Wang, TF | 1 |
| Yee, GC | 1 |
| Zakarija, A | 1 |
| McMillian, N | 1 |
| Engh, AM | 1 |
| Linder, KE | 1 |
| Nolan, WC | 1 |
| Stephenson, ML | 1 |
| Serra, AE | 1 |
| Neeper, JM | 1 |
| Caballero, DC | 1 |
| McNulty, J | 1 |
| Walker, CK | 1 |
| Sandmann, EA | 1 |
| Horyna, TJ | 1 |
| Gales, MA | 1 |
| Mahaffey, KW | 1 |
| Tonev, ST | 1 |
| Spinler, SA | 3 |
| Levine, GN | 1 |
| Gallo, R | 1 |
| Ducas, J | 1 |
| Goodman, SG | 2 |
| Antman, EM | 2 |
| Becker, RC | 1 |
| Langer, A | 1 |
| White, HD | 1 |
| Aylward, PE | 1 |
| Col, JJ | 1 |
| Ferguson, JJ | 1 |
| Califf, RM | 1 |
| Albaladejo, P | 1 |
| Ou, FS | 1 |
| Roe, MT | 1 |
| Gibler, WB | 1 |
| Ohman, EM | 1 |
| Pollack, CV | 1 |
| Alexander, KP | 1 |
| Peterson, ED | 1 |
| Barras, MA | 2 |
| Duffull, SB | 4 |
| Atherton, JJ | 2 |
| Green, B | 3 |
| Silvain, J | 1 |
| Beygui, F | 1 |
| Ankri, A | 1 |
| Bellemain-Appaix, A | 1 |
| Pena, A | 1 |
| Barthelemy, O | 1 |
| Cayla, G | 1 |
| Gallois, V | 1 |
| Galier, S | 1 |
| Costagliola, D | 1 |
| Collet, JP | 1 |
| Montalescot, G | 1 |
| Jones, JW | 1 |
| Medico, CJ | 1 |
| Walsh, P | 1 |
| Lewis, TV | 1 |
| Johnson, PN | 1 |
| Nebbia, AM | 1 |
| Dunlap, M | 1 |
| DeDea, L | 1 |
| Richard, AA | 1 |
| Kim, S | 1 |
| Moffett, BS | 1 |
| Bomgaars, L | 1 |
| Mahoney, D | 1 |
| Yee, DL | 1 |
| Kaul, B | 1 |
| Vallejo, MC | 1 |
| Ramanathan, S | 1 |
| Mandell, GL | 1 |
| Krohner, RG | 1 |
| Sanderink, GJ | 1 |
| Le Liboux, A | 1 |
| Jariwala, N | 1 |
| Harding, N | 1 |
| Ozoux, ML | 1 |
| Shukla, U | 1 |
| Montay, G | 1 |
| Boutouyrie, B | 1 |
| Miro, A | 1 |
| Frederiksen, SG | 1 |
| Hedenbro, JL | 1 |
| Norgren, L | 1 |
| Inverso, SM | 1 |
| Cohen, M | 1 |
| Stringer, KA | 1 |
| Vincenzi, B | 1 |
| Santini, D | 1 |
| Avvisati, G | 1 |
| Borzomati, D | 1 |
| Tonini, G | 1 |
| Alikhan, R | 1 |
| Cohen, AT | 2 |
| Combe, S | 1 |
| Samama, MM | 1 |
| Desjardins, L | 1 |
| Eldor, A | 1 |
| Janbon, C | 1 |
| Leizorovicz, A | 2 |
| Olsson, CG | 2 |
| Turpie, AG | 2 |
| Fareed, J | 1 |
| Hoppensteadt, D | 1 |
| Walenga, J | 1 |
| Iqbal, O | 1 |
| Ma, Q | 1 |
| Jeske, W | 1 |
| Sheikh, T | 1 |
| Bazinet, A | 1 |
| Almanric, K | 1 |
| Brunet, C | 1 |
| Turcotte, I | 1 |
| Martineau, J | 1 |
| Caron, S | 1 |
| Blais, N | 1 |
| Lalonde, L | 1 |
| Spinler, S | 1 |
| Davidson, BL | 1 |
| Büller, HR | 1 |
| Decousus, H | 1 |
| Gallus, A | 1 |
| Gent, M | 1 |
| Piovella, F | 1 |
| Prins, MH | 1 |
| Raskob, GE | 1 |
| Segers, AE | 1 |
| Lensing, AW | 1 |
| Ellison, J | 1 |
| Thomson, AJ | 1 |
| Conkie, JA | 1 |
| McCall, F | 1 |
| Walker, D | 1 |
| Greer, A | 1 |
| Perry, DJ | 1 |
| Haines, ST | 1 |
| Dager, WE | 1 |
| Trujillo, TC | 1 |
| Smith, J | 1 |
| Canton, EM | 1 |
| Al-Yaseen, E | 1 |
| Wells, PS | 1 |
| Anderson, J | 1 |
| Martin, J | 1 |
| Kovacs, MJ | 1 |
| Kucher, N | 1 |
| Vaitkus, PT | 1 |
| Harenberg, J | 1 |
| Kuzin, MI | 1 |
| Kuzin, NM | 1 |
| Markov, NK | 1 |
| Leont'eva, MS | 1 |
| Gorbatov, OI | 1 |
| Romanov, MM | 1 |
| Shumbalina, LF | 1 |
| Nesterova, SG | 1 |
| Yee, JY | 1 |
| Pfrepper, C | 1 |
| Metze, M | 1 |
| Weise, M | 1 |
| Koch, E | 1 |
| Siegemund, R | 1 |
| Siegemund, A | 1 |
| Petros, S | 1 |
| Mousa, SA | 1 |
| Hainer, JW | 1 |
| Barrett, JS | 1 |
| Assaid, CA | 1 |
| Fossler, MJ | 1 |
| Cox, DS | 1 |
| Leathers, T | 1 |
| Leese, PT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily[NCT02070237] | Phase 1 | 90 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Our primary outcome will be to assess the Anti Xa level drawn 3.5-4 hours after the third dose of Lovenox (enoxaparin) to assess if this is in the prophylactic range. (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | IU/mL (Mean) |
|---|---|
| Enoxaparin Once Daily | 0.14 |
| Enoxaparin Twice Daily | 0.30 |
We will assess if any of the subjects has an Anti Xa level that is in the supraprophylactic range (treatment range). (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | participants (Number) |
|---|---|
| Enoxaparin Once Daily | 0 |
| Enoxaparin Twice Daily | 0 |
12 reviews available for dalteparin and Obesity
| Article | Year |
|---|---|
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Disease Management; Enoxaparin; Female; Humans; | 2017 |
Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies.
Topics: Analgesics; Anticoagulants; Body Mass Index; Body Weight; Clinical Trials as Topic; Elective Surgica | 2018 |
Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Venous Thromboembolism | 2013 |
[Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature].
Topics: Aged, 80 and over; Anemia, Hypochromic; Anticoagulants; Bundle-Branch Block; Diabetes Complications; | 2014 |
Pulmonary embolism in burns, is there an evidence based prophylactic recommendation? Case report and review of literature.
Topics: Adult; Anticoagulants; Burns; Enoxaparin; Evidence-Based Medicine; Female; Humans; Obesity; Pulmonar | 2015 |
Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents.
Topics: Adolescent; Analgesics, Opioid; Anesthetics; Bariatric Surgery; Benzodiazepines; Dexmedetomidine; En | 2015 |
Dosing Medications in Obese Patients.
Topics: Aminoglycosides; Dose-Response Relationship, Drug; Enoxaparin; Heparin; Humans; Inpatients; Obesity; | 2015 |
Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
Topics: Anticoagulants; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2017 |
Pharmacotherapy in the critically ill obese patient.
Topics: Aminoglycosides; Antithrombins; Arginine; Body Mass Index; Carbapenems; Cephalosporins; Drug Dosage | 2010 |
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
Topics: Age Factors; Anticoagulants; Biological Availability; Clinical Trials as Topic; Enoxaparin; Female; | 2003 |
Treating venous thromboembolism: enoxaparin.
Topics: Ambulatory Care; Anticoagulants; Contraindications; Cost-Benefit Analysis; Drug Costs; Enoxaparin; H | 2001 |
13 trials available for dalteparin and Obesity
| Article | Year |
|---|---|
Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis.
Topics: Anticoagulants; Area Under Curve; Body Weight; Chromogenic Compounds; Dose-Response Relationship, Dr | 2002 |
Standard Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis Is Not Sufficient for Most Patients Within a Trauma Intensive Care Unit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Mass Index; Dose-Response Relations | 2015 |
A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Topics: Adult; Blood Coagulation; Body Mass Index; Chemoprevention; Dose-Response Relationship, Drug; Drug A | 2016 |
Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Humans; Kidney; Ki | 2009 |
Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation Tests; Cardiac | 2010 |
Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations.
Topics: Algorithms; Anticoagulants; Drug Monitoring; Enoxaparin; Humans; Kidney Diseases; Models, Statistica | 2010 |
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; Biological Availability; Cross-Over Studies; En | 2002 |
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Dose-Response Relationship, Drug; Double-B | 2003 |
Dosage of enoxaparin among obese and renal impairment patients.
Topics: Aged; Blood Coagulation Tests; Body Weight; Cardiovascular Diseases; Drug Monitoring; Enoxaparin; Fa | 2005 |
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin; Humans; Male; Mi | 2007 |
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Cesarean Section; Dalteparin; Enoxaparin; Facto | 2001 |
Weight-based administration of dalteparin in obese patients.
Topics: Adult; Aged; Anticoagulants; Body Weight; Dalteparin; Drug Prescriptions; Factor Xa; Female; Humans; | 2003 |
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cross-Over Studies; Factor Xa Inhibitors; Femal | 2002 |
40 other studies available for dalteparin and Obesity
| Article | Year |
|---|---|
The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.
Topics: Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin; | 2023 |
[Some aspects of abdominal surgical interventions in the presence of obesity].
Topics: Anticoagulants; Cholecystitis, Acute; Female; Follow-Up Studies; Hernia, Diaphragmatic; Hernia, Vent | 2008 |
A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery.
Topics: Adult; Aged; Algorithms; Body Weight; Cohort Studies; Female; Follow-Up Studies; Heparin, Low-Molecu | 2009 |
Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male | 2022 |
Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity.
Topics: Adult; Anticoagulants; Child; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Obesity; Venous Thr | 2022 |
Improving compliance with venous thromboembolism prophylaxis guidelines in obese inpatients.
Topics: Anticoagulants; Enoxaparin; Humans; Inpatients; Obesity; Venous Thromboembolism | 2022 |
Assessment of BMI and Venous Thromboembolism Rates in Patients on Standard Chemoprophylaxis Regimens After Undergoing Free Tissue Transfer to the Head and Neck.
Topics: Anticoagulants; Body Mass Index; Chemoprevention; Cohort Studies; Enoxaparin; Female; Humans; Male; | 2022 |
Incidence of venous thromboembolism after robotic-assisted hysterectomy in obese patients with endometrial cancer: do we need extended prophylaxis?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Endometrial Neoplasms; Enoxaparin; Female; Heparin; | 2021 |
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatme | 2020 |
Clinical analysis of postoperative venous thromboembolism in Japanese patients after colorectal cancer surgery.
Topics: Aged; Anticoagulants; Asian People; Colorectal Neoplasms; Enoxaparin; Female; Fibrin Fibrinogen Degr | 2021 |
Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Prospective Studies; Venous Thromboembolism | 2021 |
Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients.
Topics: Adult; Aged; Anticoagulants; Burns; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; | 2021 |
Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy.
Topics: Anticoagulants; Bariatric Surgery; Enoxaparin; Female; Heparin; Heparin, Low-Molecular-Weight; Human | 2022 |
The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction.
Topics: Adult; Anticoagulants; Blood; Enoxaparin; Female; Humans; Maternal Serum Screening Tests; Middle Age | 2017 |
Enoxaparin: A cause of postoperative fever?
Topics: Aged; Animals; Anticoagulants; Arthroplasty, Replacement, Knee; Cattle; Diabetes Complications; Enox | 2018 |
Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
Topics: Adult; Body Weight; Drug Dosage Calculations; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; | 2019 |
Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
Topics: Anticoagulants; Body Mass Index; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up Stu | 2013 |
A 15-year-old obese girl with abdominal pain.
Topics: Abdominal Pain; Adolescent; Anticoagulants; Appendicitis; Diagnosis, Differential; Enoxaparin; Femal | 2015 |
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Dalteparin; Enoxaparin; Fondaparinux; Heparin; | 2015 |
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Body Mass Index; Comorbidity; Data | 2010 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxap | 2008 |
Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticoagulants; Body Weight; Cohort Studies; Enoxap | 2009 |
Venous thromboembolism: appropriate risk assessment and treatment can save lives.
Topics: Anticoagulants; Enoxaparin; Fatal Outcome; Female; Humans; Obesity; Ovarian Neoplasms; Pneumonia; Ri | 2010 |
Increased enoxaparin dosing is required for obese children.
Topics: Adolescent; Anticoagulants; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; E | 2011 |
Erythromycin for GI motility; sunscreens; enoxaparin in obesity.
Topics: Enoxaparin; Erythromycin; Gastrointestinal Motility; Humans; Obesity; Sunscreening Agents | 2011 |
Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
Topics: Adolescent; Anticoagulants; Case-Control Studies; Child; Child, Preschool; Drug Monitoring; Enoxapar | 2013 |
Accidental spinal analgesia in the presence of a lumboperitoneal shunt in an obese parturient receiving enoxaparin therapy.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, Spinal; Anticoagulants; Cerebrospi | 2002 |
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients.
Topics: Adult; Aged; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; Male; Middle Aged; Obesity; Pe | 2003 |
Development of a dosing strategy for enoxaparin in obese patients.
Topics: Anticoagulants; Contusions; Enoxaparin; Female; Fibrinolytic Agents; Humans; Logistic Models; Male; | 2003 |
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Ki | 2003 |
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients (Br J Surg 2003; 90: 547-548).
Topics: Anticoagulants; Antithrombin III; Body Weight; Enoxaparin; Humans; Obesity; Partial Thromboplastin T | 2003 |
Adjusting the dose of low molecular weight heparins in renally impaired and obese patients.
Topics: Anticoagulants; Biomarkers; Cardiovascular Diseases; Comorbidity; Creatinine; Dose-Response Relation | 2004 |
Clinical and management challenges in preventing venous thromboembolism in health systems: a case-based panel discussion.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Bariatric Surgery; Colonic Neoplasms; Daltepar | 2010 |
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Dalteparin; Female; Humans; Internation | 2005 |
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Humans; Logistic Models; Male; Multivar | 2005 |
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients: a rebuttal.
Topics: Bioethics; Body Weight; Dalteparin; Factor Xa; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; | 2005 |
[Effect of fragmin, a low-molecular heparin, on hemostasis in patients with alimentary-constitutional obesity].
Topics: Adult; Body Constitution; Dalteparin; Female; Hemostasis; Heparin; Humans; Male; Middle Aged; Obesit | 1993 |
The effect of body weight on dalteparin pharmacokinetics. A preliminary study.
Topics: Anticoagulants; Bayes Theorem; Biological Availability; Body Weight; Case-Control Studies; Creatinin | 2000 |
Body weight adapted tinzaparin treatment in patients with obesity.
Topics: Anticoagulants; Body Weight; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Obesity; Ti | 2022 |
Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin.
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Obesity; Tinzaparin; Tumor Necrosis Fact | 2005 |